Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0029421007
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01223DLB2
AARD
Aardvark Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Software - Application · THEMEFOLIO: $HLTH
NAME
Aardvark Therapeutics Inc
ISIN
US0029421007
TICKER
AARD
MIC
XNAS
REUTERS
AARD.OQ
BLOOMBERG
AARD US
Thu, 20.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.08.2026       Aardvark Therapeutics
US0029421007

Levi & Korsinsky, LLP notifies institutional investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between February 13, 2025 and May 14, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levi...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.08.2026       Aardvark Therapeutics
US0029421007

Law Offices of Howard G. Smith announces an investigation on behalf of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.08.2026       Aardvark Therapeutics
US0029421007

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.08.2026       Aardvark Therapeutics
US0029421007

The Law Offices of Frank R. Cruz announces an investigation of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AARDVARK THERAPEUTICS, INC. (AARD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PU...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.08.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - August 19, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documen...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.08.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges former Chief Operating Officer Bryan Jones, Ph.D. told investors in May 2025 that ARD-101 had a "very, very clean" safety profile, months before cardiac observations allegedly forced a Phase 3 pause and a full FDA clinical hold.NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Stateme...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 18.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 18, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired: (a) Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) common stock pursuant and/or traceable to the Offering D...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.08.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 17, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b)...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospec...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.08.2026       Aardvark Therapeutics
US0029421007

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) on behalf of investors that purchased or otherwise acquired Aardvark common stock pursuant and/or traceable to the Company's in...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.08.2026       Aardvark Therapeutics
US0029421007

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 16.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sat, 15.08.2026       Aardvark Therapeutics
US0029421007

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.06.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperpha...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.06.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, June 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperpha...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Aardvark Therapeutics
US0029421007

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Aardvark Therapeutics
US0029421007

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphag...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Aardvark Therapeutics
US0029421007

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphag...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphag...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Aardvark Therapeutics
US0029421007

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, April 22, 2026 /PRNewswire/ - On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperpha...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, April 10, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperph...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Aardvark Therapeutics
US0029421007

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Aardvark Therapeutics
US0029421007

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Aardvark Therapeutics
US0029421007

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NYSE: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Aardvark Therapeutics
US0029421007

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NYSE: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.02.2026       Aardvark Therapeutics
US0029421007

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or f...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.02.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimin...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.02.2026       Aardvark Therapeutics
US0029421007

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Aardvark Therapeutics
US0029421007

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Aardvark Therapeutics
US0029421007

Q32025 Earnings...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was gra...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Aardvark Therapeutics
US0029421007

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape ...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.11.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting o...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.09.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the Stifel 2025 Virtual Cardiome...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.08.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.08.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the second quarter ended June...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.08.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced new positive preclinical data demonstrating the pot...
Read more
Aardvark Therapeutics
Technical Analysis Termsheets Terminal
Permalink